950210 — Prestige Biopharma Income Statement
0.000.00%
Last trade - 00:00
- KR₩481bn
- KR₩408bn
- $0.12m
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.84 | 0 | 0 | 0 | 0.122 |
Cost of Revenue | |||||
Gross Profit | — | — | — | -18.4 | -18.6 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 5.72 | 9.09 | 16.2 | 109 | 64.2 |
Operating Profit | -3.88 | -9.09 | -16.2 | -109 | -64.1 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1.11 | -12.5 | -6.48 | -175 | -1.58 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.27 | -12.5 | -6.51 | -176 | -2.16 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -1.27 | -12.5 | -6.51 | -176 | 13.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.27 | -12.5 | -6.51 | -176 | 13.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.106 | -1.04 | -0.63 | -11.4 | 1.72 |